{"title": "Vacunas antineumoc\u00f3cicas tempranas y en combinaci\u00f3n (PREVIX_COMBO)", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT01174849", "hostname": "ichgcp.net", "description": "El prop\u00f3sito de este estudio es determinar si un programa temprano de una combinaci\u00f3n de tres dosis de PHiD-CV y una dosis de PCV13 es superior a tres dosis de.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2010-08-02", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Vacunas antineumoc\u00f3cicas tempranas y en combinaci\u00f3n (PREVIX_COMBO)\n[Menzies School of Health Research](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Menzies%20School%20of%20Health%20Research)\nUn ensayo controlado aleatorizado de vacunas neumoc\u00f3cicas conjugadas Synflorix y Prevenar13 en secuencia o solas en beb\u00e9s ind\u00edgenas de alto riesgo (PREV-IX_COMBO): resultados de inmunogenicidad, portaci\u00f3n y otitis media\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nLos ni\u00f1os abor\u00edgenes del Territorio del Norte (NT) tienen altas tasas de otitis media causada por H. influenzae no capsular (NCHi) y neumococos. La vacuna antineumoc\u00f3cica conjugada ha reducido eficazmente la enfermedad causada por los 7 serotipos. Las tasas de otitis media (OM) del serotipo no relacionado con la vacuna, en particular el 19A, est\u00e1n aumentando, y la NCHi contin\u00faa siendo un pat\u00f3geno importante en las perforaciones. Los paralelismos con la neumon\u00eda son muy probables en esta poblaci\u00f3n. Se necesitan vacunas con protecci\u00f3n ampliada y temprana.\nA principios de 2009, la vacuna neumoc\u00f3cica H. influenzae prote\u00edna D conjugada de GSK (PHiD-CV) obtuvo la licencia en Australia. En comparaci\u00f3n con la vacuna actual, 7PCV, esta vacuna ofrece protecci\u00f3n contra los serotipos neumoc\u00f3cicos 1, 5, 7F y NCHi (que es un pat\u00f3geno principal de la OM y posiblemente de la neumon\u00eda). Sin embargo, para 2010, una nueva generaci\u00f3n de 7PCV de Wyeth, PCV13, tambi\u00e9n tendr\u00e1 licencia en Australia. En comparaci\u00f3n con PHiD-CV, esta vacuna ofrece protecci\u00f3n contra los serotipos adicionales 3, 6A y 19A; sin embargo, no ofrece protecci\u00f3n contra la infecci\u00f3n por NCHi. No hay evidencia emp\u00edrica que sugiera que cualquiera de las vacunas tendr\u00e1 una eficacia cl\u00ednica superior para la otitis media o la neumon\u00eda en ni\u00f1os de alto riesgo. La nueva estrategia de combinaci\u00f3n propuesta para este ensayo tiene el potencial de brindar lo mejor de ambas vacunas.\nTipo de estudio\nInscripci\u00f3n (Actual)\nFase\n- Fase 4\nContactos y Ubicaciones\nUbicaciones de estudio\n-\nAustralia\n-\nNorthern Territory\n-\nDarwin, Northern Territory, Australia, 0811\n- Menzies School of Health Research\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nG\u00e9neros elegibles para el estudio\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\ninfantes ind\u00edgenas\n- 4 a 6 semanas de edad\n- Viven en comunidades remotas que han proporcionado expresiones de inter\u00e9s firmadas para participar en el ensayo PREV-IX_COMBO\n- Tienen la intenci\u00f3n de permanecer en su comunidad hasta que su beb\u00e9 tenga 7 meses de edad.\n- Elegible para vacunas de rutina.\nCriterio de exclusi\u00f3n:\n- Reacci\u00f3n adversa previa a las vacunas antineumoc\u00f3cicas conjugadas seg\u00fan el Manual de Inmunizaci\u00f3n Australiano.\n- Edad gestacional < 32 semanas\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Prevenci\u00f3n\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: Ninguno (etiqueta abierta)\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nComparador activo: Sinflorix\n|\n|\nLa vacuna decavalente contiene 1 \u00b5g de polisac\u00e1rido capsular purificado de neumococo serotipos 1, 5, 6B, 7F, 9V, 14 y 23F conjugado a prote\u00edna D, 3 \u00b5g de serotipo 4 conjugado a prote\u00edna D, 3 \u00b5g de serotipo 18C conjugado al toxoide tet\u00e1nico y 3 \u00b5g del serotipo 19F conjugado al toxoide dift\u00e9rico.\nOtros nombres:\n|\n|\nComparador activo: Prevenar13\n|\n|\nLa vacuna es una suspensi\u00f3n blanca homog\u00e9nea lista para usar para inyecci\u00f3n intramuscular, que se suministra en una jeringa precargada.\nIngredientes activos\nCada dosis de 0,5 ml contiene:\n2,2 \u03bcg de polisac\u00e1ridos capsulares purificados de neumococo para los serotipos 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F y 23F 4,4 \u03bcg de polisac\u00e1ridos capsulares purificados de neumococo para el serotipo 6B. Cada serotipo se conjuga individualmente con la prote\u00edna dift\u00e9rica CRM197 no t\u00f3xica y se adsorbe en fosfato de aluminio (0,565 mg). CRM197 es una variante no t\u00f3xica de la toxina dift\u00e9rica aislada de cultivos de Corynebacterium diphtheriae cepa C7 (\u03b2197) cultivados en un medio basado en extracto de levadura y \u00e1cidos casamino.\nOtros nombres:\n|\n|\nExperimental: COMBO\nESQUEMA DE COMBINACI\u00d3N de la vacuna de comparaci\u00f3n 1 y la vacuna de comparaci\u00f3n 2 Synflorix a los 1, 2 y 4 meses y luego Prevenar13 a los 6 meses.\n|\n|\nESQUEMA DE COMBINACI\u00d3N de vacuna 1 y vacuna 2: Synflorix (PHiD-CV) a los 1,2,4 meses y luego Prevenar13 (PCV13) a los 6 meses de edad.\nOtros nombres:\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nInmunogenicidad\nPeriodo de tiempo: 7 meses de edad\n|\n|\nA los 7 meses de edad, la concentraci\u00f3n general y espec\u00edfica del serotipo (particularmente el serotipo 19A y HiD) a Concentraci\u00f3n media geom\u00e9trica (GMC) de IgG b Proporci\u00f3n de ni\u00f1os con IgG GMC por encima del umbral (0,35 microg/mL)\n|\n|\n7 meses de edad\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\ncarro nasofar\u00edngeo\nPeriodo de tiempo: 7 meses de edad\n|\n|\nA los 7 meses de edad, la proporci\u00f3n de ni\u00f1os portadores de neumococos del serotipo 19A\n|\n|\n7 meses de edad\n|\n|\ncarro nasofar\u00edngeo\nPeriodo de tiempo: 7 meses de edad\n|\n|\nA los 7 meses de edad, la proporci\u00f3n de ni\u00f1os portadores de H. influenzae no capsular.\n|\n|\n7 meses de edad\n|\n|\notitis media\nPeriodo de tiempo: 7 meses de edad\n|\n|\nA los 7 meses de edad, la proporci\u00f3n de ni\u00f1os con alguna otitis media.\n|\n|\n7 meses de edad\nColaboradores e Investigadores\nPatrocinador\nPublicaciones y enlaces \u00fatiles\nPublicaciones Generales\n-\n[Morris PS, Leach AJ, Silberberg P, Mellon G, Wilson C, Hamilton E, Beissbarth J. Otitis media in young Aboriginal children from remote communities in Northern and Central Australia: a cross-sectional survey. BMC Pediatr. 2005 Jul 20;5:27. doi: 10.1186/1471-2431-5-27.](https://ichgcp.net/es/clinical-trials-registry/publications/45449-otitis-media-in-young-aboriginal-children-from-remote-communities-in-northern-and-central-australia)\n-\n[Leach AJ, Morris PS. The burden and outcome of respiratory tract infection in Australian and aboriginal children. Pediatr Infect Dis J. 2007 Oct;26(10 Suppl):S4-7. doi: 10.1097/INF.0b013e318154b238.](https://pubmed.ncbi.nlm.nih.gov/18049380)\n-\n[Leach AJ, Morris PS, Mathews JD; Chronic Otitis Media Intervention Trial - One (COMIT1) group. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatr. 2008 Jun 2;8:23. doi: 10.1186/1471-2431-8-23.](https://ichgcp.net/es/clinical-trials-registry/publications/46201-compared-to-placebo-long-term-antibiotics-resolve-otitis-media-with-effusion-ome-and-prevent-acute)\n-\n[Leach AJ, Morris PS, Mackenzie G, McDonnell J, Balloch A, Carapetis J, Tang M. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population. Vaccine. 2008 Jul 23;26(31):3885-91. doi: 10.1016/j.vaccine.2008.05.012. Epub 2008 May 27.](https://pubmed.ncbi.nlm.nih.gov/18562052)\n-\n[Leach AJ, Morris PS, McCallum GB, Wilson CA, Stubbs L, Beissbarth J, Jacups S, Hare K, Smith-Vaughan HC. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis. 2009 Aug 4;9:121. doi: 10.1186/1471-2334-9-121.](https://ichgcp.net/es/clinical-trials-registry/publications/46202-emerging-pneumococcal-carriage-serotypes-in-a-high-risk-population-receiving-universal-7-valent)\n-\n[Mackenzie GA, Carapetis JR, Leach AJ, Morris PS. Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination. BMC Pediatr. 2009 Feb 19;9:14. doi: 10.1186/1471-2431-9-14.](https://ichgcp.net/es/clinical-trials-registry/publications/46203-pneumococcal-vaccination-and-otitis-media-in-australian-aboriginal-infants-comparison-of-two-birth)\n-\n[Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J. 1994 Nov;13(11):983-9. doi: 10.1097/00006454-199411000-00009.](https://pubmed.ncbi.nlm.nih.gov/7845752)\n-\n[Smith-Vaughan H, Byun R, Nadkarni M, Jacques NA, Hunter N, Halpin S, Morris PS, Leach AJ. Measuring nasal bacterial load and its association with otitis media. BMC Ear Nose Throat Disord. 2006 May 10;6:10. doi: 10.1186/1472-6815-6-10.](https://ichgcp.net/es/clinical-trials-registry/publications/46204-measuring-nasal-bacterial-load-and-its-association-with-otitis-media)\n-\n[Hare KM, Morris P, Smith-Vaughan H, Leach AJ. Random colony selection versus colony morphology for detection of multiple pneumococcal serotypes in nasopharyngeal swabs. Pediatr Infect Dis J. 2008 Feb;27(2):178-80. doi: 10.1097/INF.0b013e31815bb6c5.](https://pubmed.ncbi.nlm.nih.gov/18174871)\n-\n[Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006 Mar 4;367(9512):740-8. doi: 10.1016/S0140-6736(06)68304-9.](https://pubmed.ncbi.nlm.nih.gov/16517274)\n-\n[Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R; Enhanced Invasive Pneumococcal Disease Surveillance Working Group, Brown M, Gilbert L, Hogg G, Murphy D; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep. 2008 Mar;32(1):18-30.](https://ichgcp.net/es/clinical-trials-registry/publications/46205-invasive-pneumococcal-disease-in-australia-2006)\n-\n[Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Chatfield MD, Lehmann D, Binks M, Chang AB, Carapetis J, Krause V, Andrews R, Snelling T, Skull SA, Licciardi PV, Oguoma VM, Morris PS. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials. Lancet Infect Dis. 2022 Sep;22(9):1374-1387. doi: 10.1016/S1473-3099(22)00272-9. Epub 2022 Jun 27.](https://pubmed.ncbi.nlm.nih.gov/35772449)\n-\n[Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Wilson N, Arrowsmith B, Beissbarth J, Chatfield MD, Oguoma VM, Morris PS. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial. BMC Pediatr. 2021 Mar 8;21(1):117. doi: 10.1186/s12887-021-02552-z.](https://ichgcp.net/es/clinical-trials-registry/publications/46206-otitis-media-outcomes-of-a-combined-10-valent-pneumococcal-haemophilus-influenzae-protein-d)\n-\n[Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, Brown NJ, McIntyre P, Smith-Vaughan H, Skull S, Balloch A, Andrews R, Carapetis J, McDonnell J, Krause V, Morris PS. Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial. BMJ Open. 2015 Jan 16;5(1):e007247. doi: 10.1136/bmjopen-2014-007247.](https://ichgcp.net/es/clinical-trials-registry/publications/46207-pneumococcal-conjugate-vaccines-prevenar13-and-synflorix-in-sequence-or-alone-in-high-risk)\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio\nFinalizaci\u00f3n primaria (Actual)\nFinalizaci\u00f3n del estudio (Actual)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (Estimar)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- 605810\n- ACTRN12610000544077 (Identificador de registro: Australia New Zealand Clinical Trials Registry (ANZCTR))\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Otitis media\n-\nNCT06034080A\u00fan no reclutando\n[Intervenciones para eliminar la prescripci\u00f3n innecesaria de antibi\u00f3ticos para ni\u00f1os con infecciones de o\u00eddo (DISAPEAR)](https://ichgcp.net/es/clinical-trials-registry/NCT06034080)Enfermedad infecciosa pedi\u00e1trica | Otitis media aguda | Infecci\u00f3n en el o\u00eddo\n-\nNCT06027593Reclutamiento\n[Uso de informes automatizados derivados electr\u00f3nicamente sobre el uso apropiado de antibi\u00f3ticos para informar las intervenciones de gesti\u00f3n (EMPOWER)](https://ichgcp.net/es/clinical-trials-registry/NCT06027593)Faringitis | Otitis media aguda | La comunidad adquiri\u00f3 neumon\u00eda\n-\nNCT06005337ReclutamientoPadres | LLA pedi\u00e1trica | Bronquiolitis | Resfriado comun | Faringitis | Otitis media aguda | Asma aguda\n-\nNCT05915078Reclutamiento\n[Evaluaci\u00f3n de los resultados despu\u00e9s de una timpanostom\u00eda en el consultorio con el sistema Tula\u00ae: un registro prospectivo multic\u00e9ntrico](https://ichgcp.net/es/clinical-trials-registry/NCT05915078)Otitis media | Otitis media con derrame | Otitis media aguda\n-\nNCT05804123ReclutamientoInfecciones del Tracto Respiratorio Superior\n-\nNCT05799404A\u00fan no reclutandoOtitis media | Otoesclerosis\n-\nNCT05741333ReclutamientoOtitis media | Infecci\u00f3n en el o\u00eddo\n-\nNCT05651633ReclutamientoDolor | Otitis media aguda\n-\nNCT05608993A\u00fan no reclutandoEnfermedad infecciosa pedi\u00e1trica | Otitis media aguda | Infecci\u00f3n en el o\u00eddo\n-\nNCT05545345A\u00fan no reclutandoOtitis media con derrame en ni\u00f1os\nEnsayos cl\u00ednicos sobre Sinflorix\n-\nNCT05455294ReclutamientoLeucemia mieloide aguda | S\u00edndromes mielodispl\u00e1sicos | Mielofibrosis | Malignidad mieloide | Neoplasia mieloproliferativa\n-\nNCT02961231ReclutamientoNeumon\u00eda, Neumoc\u00f3cica\n-\nNCT01953510TerminadoVacunas Antineumoc\u00f3cicas\n-\nNCT03636906Terminado\n[Vacuna en investigaci\u00f3n contra el virus respiratorio sincitial (RSV) en beb\u00e9s de 6 y 7 meses de edad que probablemente no est\u00e9n expuestos al RSV](https://ichgcp.net/es/clinical-trials-registry/NCT03636906)Infecciones por virus respiratorio sincitial\n-\nNCT03896477Terminado\n-\nNCT01485406Terminado\n-\nNCT00624819Terminado\n[Evaluaci\u00f3n de la persistencia de anticuerpos en ni\u00f1os vacunados previamente con la vacuna antineumoc\u00f3cica conjugada](https://ichgcp.net/es/clinical-trials-registry/NCT00624819)Vacunas contra Streptococcus pneumoniae | Infecciones Estreptoc\u00f3cicas\n-\nNCT01144663Terminado\n[Inmunogenicidad y seguridad de la vacuna meningoc\u00f3cica GSK 134612 coadministrada con vacunas neumoc\u00f3cica y DTPa-HBV-IPV/Hib](https://ichgcp.net/es/clinical-trials-registry/NCT01144663)Infecciones Meningoc\u00f3cicas | Vacunas meningoc\u00f3cicas\n-\nNCT04551248Desconocido\n[Evaluaci\u00f3n de seguridad posterior a la comercializaci\u00f3n de vacunas neumoc\u00f3cicas entre ni\u00f1os y adultos mayores.](https://ichgcp.net/es/clinical-trials-registry/NCT04551248)Reacci\u00f3n adversa a la vacuna antineumoc\u00f3cica\n-\nNCT03197376Terminado", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT01174849", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT01174849&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT01174849", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Menzies%20School%20of%20Health%20Research", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Otitis%20Media", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Synflorix", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prevenar13", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=COMBO", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Synflorix", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prevenar13", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=COMBO", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Menzies%20School%20of%20Health%20Research", "https://ichgcp.net/es/clinical-trials-registry/publications/45449-otitis-media-in-young-aboriginal-children-from-remote-communities-in-northern-and-central-australia", "https://pubmed.ncbi.nlm.nih.gov/18049380", "https://ichgcp.net/es/clinical-trials-registry/publications/46201-compared-to-placebo-long-term-antibiotics-resolve-otitis-media-with-effusion-ome-and-prevent-acute", "https://pubmed.ncbi.nlm.nih.gov/18562052", "https://ichgcp.net/es/clinical-trials-registry/publications/46202-emerging-pneumococcal-carriage-serotypes-in-a-high-risk-population-receiving-universal-7-valent", "https://ichgcp.net/es/clinical-trials-registry/publications/46203-pneumococcal-vaccination-and-otitis-media-in-australian-aboriginal-infants-comparison-of-two-birth", "https://pubmed.ncbi.nlm.nih.gov/7845752", "https://ichgcp.net/es/clinical-trials-registry/publications/46204-measuring-nasal-bacterial-load-and-its-association-with-otitis-media", "https://pubmed.ncbi.nlm.nih.gov/18174871", "https://pubmed.ncbi.nlm.nih.gov/16517274", "https://ichgcp.net/es/clinical-trials-registry/publications/46205-invasive-pneumococcal-disease-in-australia-2006", "https://pubmed.ncbi.nlm.nih.gov/35772449", "https://ichgcp.net/es/clinical-trials-registry/publications/46206-otitis-media-outcomes-of-a-combined-10-valent-pneumococcal-haemophilus-influenzae-protein-d", "https://ichgcp.net/es/clinical-trials-registry/publications/46207-pneumococcal-conjugate-vaccines-prevenar13-and-synflorix-in-sequence-or-alone-in-high-risk", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Australia", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=high-risk%20children", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=randomised%20controlled%20trial", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=pneumococcal%20vaccines", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=otitis%20media", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=indigenous", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Otorhinolaryngologic%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ear%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Otitis", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Otitis%20Media", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Heptavalent%20Pneumococcal%20Conjugate%20Vaccine", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06034080", "https://ichgcp.net/es/clinical-trials-registry/NCT06027593", "https://ichgcp.net/es/clinical-trials-registry/NCT06005337", "https://ichgcp.net/es/clinical-trials-registry/NCT05915078", "https://ichgcp.net/es/clinical-trials-registry/NCT05804123", "https://ichgcp.net/es/clinical-trials-registry/NCT05799404", "https://ichgcp.net/es/clinical-trials-registry/NCT05741333", "https://ichgcp.net/es/clinical-trials-registry/NCT05651633", "https://ichgcp.net/es/clinical-trials-registry/NCT05608993", "https://ichgcp.net/es/clinical-trials-registry/NCT05545345", "https://ichgcp.net/es/clinical-trials-registry/NCT05455294", "https://ichgcp.net/es/clinical-trials-registry/NCT02961231", "https://ichgcp.net/es/clinical-trials-registry/NCT01953510", "https://ichgcp.net/es/clinical-trials-registry/NCT03636906", "https://ichgcp.net/es/clinical-trials-registry/NCT03896477", "https://ichgcp.net/es/clinical-trials-registry/NCT01485406", "https://ichgcp.net/es/clinical-trials-registry/NCT00624819", "https://ichgcp.net/es/clinical-trials-registry/NCT01144663", "https://ichgcp.net/es/clinical-trials-registry/NCT04551248", "https://ichgcp.net/es/clinical-trials-registry/NCT03197376", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/belgium", "https://ichgcp.net/es/cro-list/country/cambodia", "https://ichgcp.net/es/cro-list/country/congo", "https://ichgcp.net/es/cro-list/country/egypt", "https://ichgcp.net/es/cro-list/country/gambia", "https://ichgcp.net/es/cro-list/country/indonesia", "https://ichgcp.net/es/cro-list/country/myanmar", "https://ichgcp.net/es/cro-list/country/pakistan", "https://ichgcp.net/es/cro-list/country/serbia", "https://ichgcp.net/es/cro-list/country/south_africa", "https://ichgcp.net/es/cro-list/country/tunisia", "https://ichgcp.net/es/cro-list/country/venezuela", "https://ichgcp.net/es/cro-list/country/vietnam", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/south_africa/company/across_global", "https://ichgcp.net/es/cro-list/country/south_africa/company/medpace", "https://ichgcp.net/es/cro-list/country/south_africa/company/psi", "https://ichgcp.net/es/cro-list/country/south_africa/company/dokumeds", "https://ichgcp.net/es/cro-list/country/south_africa/company/icon", "https://ichgcp.net/es/cro-list/country/south_africa/company/parexel", "https://ichgcp.net/es/cro-list/country/south_africa/company/pra_health_sciences", "https://ichgcp.net/es/cro-list/country/south_africa/company/ppd", "https://ichgcp.net/es/cro-list/country/south_africa/company/celero", "https://ichgcp.net/es/cro-list/country/south_africa/company/farmovs", "https://ichgcp.net/es/cro-list/country/south_africa", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT01174849", "https://ichgcp.net/de/clinical-trials-registry/NCT01174849", "https://ichgcp.net/clinical-trials-registry/NCT01174849", "https://ichgcp.net/es/clinical-trials-registry/NCT01174849", "https://ichgcp.net/fr/clinical-trials-registry/NCT01174849", "https://ichgcp.net/it/clinical-trials-registry/NCT01174849", "https://ichgcp.net/hu/clinical-trials-registry/NCT01174849", "https://ichgcp.net/nl/clinical-trials-registry/NCT01174849", "https://ichgcp.net/no/clinical-trials-registry/NCT01174849", "https://ichgcp.net/pl/clinical-trials-registry/NCT01174849", "https://ichgcp.net/pt/clinical-trials-registry/NCT01174849", "https://ichgcp.net/fi/clinical-trials-registry/NCT01174849", "https://ichgcp.net/sv/clinical-trials-registry/NCT01174849", "https://ichgcp.net/cs/clinical-trials-registry/NCT01174849", "https://ichgcp.net/ru/clinical-trials-registry/NCT01174849", "https://ichgcp.net/ja/clinical-trials-registry/NCT01174849", "https://ichgcp.net/zh/clinical-trials-registry/NCT01174849", "https://ichgcp.net/ko/clinical-trials-registry/NCT01174849", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}